What are the update on NUT carcinoma?
NUT carcinoma is a rare and highly aggressive malignancy that primarily occurs in midline structures such as the lung, head, and neck. It is characterized by a fusion rearrangement mutation of the NUTM1 gene with various partners. Diagnosis of NUT carcinoma requires immunohistochemistry, fluorescent in situ hybridization, or genomic analysis to detect the fusion mutation. Survival rates are typically low, with few long-term survivors. Current treatment approaches, including chemotherapy and BET and histone deacetylase inhibitors, have shown limited efficacy. However, recent studies suggest a potential role for immune checkpoint inhibitors in NUT carcinoma treatment, even in the absence of high tumor mutation burden or PD-L1 positivity. RNA sequencing has identified multiple potentially targetable genes in NUT carcinoma, providing opportunities for personalized treatment. Further research is ongoing to evaluate the effectiveness of targeted therapies, including BET inhibitors, and to raise awareness of this underdiagnosed cancer entity.
Answers from top 4 papers
Papers (4) | Insight |
---|---|
The provided paper discusses the clinical and pathological characteristics, treatment strategies, and research progress of NUT carcinoma. It mentions that chemotherapy, radiotherapy, immunotherapy, and targeted therapy have been used in treatment, but the effectiveness of targeted therapy and immunotherapy is limited. The paper suggests that further research is needed to improve treatment and prognosis. However, it does not provide specific updates on NUT carcinoma beyond these findings. | |
The paper discusses the underdiagnosis of NUT carcinoma (NC) and the lack of awareness surrounding it. It mentions that there are currently no standard-of-care treatment options for NC, but novel therapies, including BET inhibitors, are being investigated. No specific updates on NC are mentioned in the paper. | |
The paper discusses the current approaches to treatment for NUT midline carcinoma, including surgery, radiation, chemotherapy, BET inhibitors, histone deacetylase inhibitors, and immune checkpoint inhibitors. However, there are no clearly effective systemic treatments for NMC. | |
The paper provides a retrospective analysis of NUT carcinoma (NC), a rare and aggressive carcinoma with no standard treatment options. It discusses the characteristics of NC patients and suggests that immune checkpoint inhibitors may be a potential treatment option for NC. However, there is no specific update mentioned in the paper. |